source
- Alnylam cuts TTR franchise guidance, market cap loses $10.8B as shares tumble 28%Alnylam announced a reduction in its full-year revenue outlook for its transthyretin (TTR) franchise, trimming the midpoint by $200 million. The company now projects TTR therapy sales of $4.2 bill…
- Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%Novo Nordisk's IL-6 inhibitor ziltivekimab failed to reduce the risk of cardiovascular events in the late-stage trial, dashing hopes for an edge in the hyper-competitive cardiometabolic space.BioSpace · 2h ago↗ source